GlaxoSmithKline’s Arzerra Gets Better CLL Label, But Now Faces Competition With Gazyva
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline exec Klaus Edvardsen says the new label should give drug a boost, as previous indication was very restrictive. Approved in 2009, Arzerra had just £75 million in 2013 worldwide sales.